Alembic Pharmaceuticals has received USFDA approvals for its generic Deferasirox tablets used for treatment of chronic iron overload due to blood transfusions in patients over two years of age.
The drug Deferasirox tablets for oral suspension will be produced in the strengths of 125 mg, 250 mg, and 500 mg. It may be noted that, the tablets are generic versions of Novartis Pharmaceuticals Corporation’s Jadenu tablets and Exjade tablets for oral suspension in the same strengths.
According to market estimates, market size for Deferasirox tablets in the strengths of 90 mg and 360 mg was $ 415 million for the 12 months ending December 2018.
Company Profile : Alembic Pharmaceuticals Ltd